Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021, 63061-63067 [2021-24921]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
assignment and transfer of Arizona
fourth-priority Colorado River water in
the amount of 762 acre-feet per year
from CVIDD to be divided amongst the
Beneficiaries. Amend CVIDD’s Colorado
River water delivery contract No. 2–07–
30–W0028 to decrease its Colorado
River water entitlement from 8,204.52 to
7,442.52 acre-feet per year. Enter into
Colorado River water delivery contracts
for Arizona fourth-priority Colorado
River water entitlements under contract
No. 21–XX–30–W0717 with The Cibola
Sportsman’s Club, Inc. for 216 acre-feet
per year, contract No. 21–XX–30–
W0718 with Alfred F. and Erma Jean
Bishop Family Trust for 420 acre-feet
per year, and contract No. 21–XX–30–
W0719 with Bruce and Lora Cathcart
and James and Maria Cathcart for 126
acre-feet per year.
21. City of Needles, BCP, California:
Approve a new point of diversion under
contract No. 05–XX–30–W0445, as
amended, dated March 16, 2007, and
contract No. 2–07–30–W0280, as
amended, dated July 3, 2002, and revise
the necessary exhibits of the abovereferenced contracts to add an
additional point of diversion.
Columbia-Pacific Northwest—Interior
Region 9: Bureau of Reclamation, 1150
North Curtis Road, Suite 100, Boise,
Idaho 83706–1234, telephone 208–378–
5344.
The Columbia-Pacific Northwest—
Interior Region 9 has no updates to
report for this quarter.
California-Great Basin—Interior
Region 10: Bureau of Reclamation, 2800
Cottage Way, Sacramento, California
95825–1898, telephone 916–978–5250.
Discontinued contract action:
3. Contractors from the Delta Division,
Cross Valley Canal, and West San
Joaquin Division; CVP; California:
Renewal of 10 interim and long-term
water service contracts; water quantities
for these contracts total in excess of
148,000 acre-feet. These contract actions
will be accomplished through long-term
renewal contracts pursuant to Public
Law 102–575. Prior to completion of
negotiation of long-term renewal
contracts, existing interim renewal
water service contracts may be renewed
through successive interim renewal of
contracts.
Completed contract actions:
40. Tehama-Colusa Canal Authority,
CVP, California: Renewal of OM&R
contract. Contract completed on
September 28, 2021.
42. Shasta County Water Agency,
CVP, California: Proposed partial
assignment of 50 acre-feet of the Shasta
County Water Agency’s CVP water
supply to the City of Shasta Lake for
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
M&I use. Contract completed on August
9, 2021.
43. Friant Water Authority, CVP,
California: Negotiation and execution of
a repayment contract for Friant Kern
Canal Middle Reach Capacity Correction
Project. Contract completed on
September 23, 2021.
Christopher Beardsley,
Director, Policy and Programs.
[FR Doc. 2021–24762 Filed 11–12–21; 8:45 am]
BILLING CODE 4332–90–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–688F]
Final Adjusted Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2021
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
This final order establishes
the final adjusted 2021 aggregate
production quotas for controlled
substances in schedules I and II of the
Controlled Substances Act and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES: This order is effective November
15, 2021.
FOR FURTHER INFORMATION CONTACT:
Scott A. Brinks, Regulatory Drafting and
Policy Support Section, Diversion
Control Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, VA
22152, Telephone: (571) 362–3261.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Legal Authority
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
(APQ) for each basic class of controlled
substances listed in schedules I and II
and for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. The Attorney
General has delegated this function to
the Administrator of the Drug
Enforcement Administration (DEA)
pursuant to 28 CFR 0.100.
Background
DEA published the 2021 established
APQ for controlled substances in
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
63061
schedules I and II and for the
assessment of annual needs (AAN) for
the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine in the Federal
Register on November 30, 2020. 85 FR
76604. DEA is committed to preventing
and limiting diversion by enforcing laws
and regulations regarding controlled
substances and the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, while meeting
the legitimate medical, scientific, and
export needs of the United States. This
notice stated that the Administrator
would adjust, as needed, the established
APQ in 2021 in accordance with 21 CFR
1303.13 and 21 CFR 1315.13.
The 2021 proposed adjusted APQ for
controlled substances in schedules I and
II and AAN for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine were
subsequently published in the Federal
Register on September 2, 2021, (86 FR
49346), after consideration of the
criteria outlined in that notice. All
interested persons were invited to
comment on or object to the proposed
APQs and AANs on or before October 4,
2021.
Comments Received
DEA received 27 timely comments in
response to the September Federal
Register notice from patients, DEAregistered entities, and non-DEA
entities. The comments included
appreciation of DEA’s response to the
increased interest in research using
hallucinogenic controlled substances,
requests to increase the APQ for
additional hallucinogenic controlled
substances, requests to increase the APQ
for select schedule II controlled
substances, concerns regarding the
inability to comment to the notice
electronically for two weeks, and
comments outside the scope of this final
order.
Issue: Commenters expressed
appreciation of DEA’s flexibility in
responding to the nationwide public
interest in hallucinogenic controlled
substances research.
DEA Response: DEA acknowledges
the expressions of appreciation to
changes in the APQ for these controlled
substances. The adjustments to select
hallucinogenic schedule I controlled
substances occurred after DEA received
additional schedule I researcher
protocols from DEA registered
researchers and quota applications from
DEA registered manufacturers.
Issue: Commenters requested DEA to
increase the APQ for Bufotenine,
Dimethyltryptamine (DMT), N,NDimethyltryptamine, 5-Methoxy-N,N-
E:\FR\FM\15NON1.SGM
15NON1
khammond on DSKJM1Z7X2PROD with NOTICES
63062
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
dimethyltryptamine (5MEODMT),
Ibogaine, Ketamine, Lysergic Acid
Diethylamide (LSD), 3,4Methylenedioxymethamphetamine
(MDMA), Mescaline, Mitragynine, and
Psilocybin in response to the
nationwide public interest in
hallucinogenic controlled substances
research.
DEA Response: Ketamine is a
schedule III controlled substance and
therefore is outside of the scope of this
final order as DEA only sets APQs for
substances controlled in schedules I and
II. DEA received additional quota
applications for DMT, MDMA, and
Psilocybin and considered the timely
provided information in those
applications for this final order.
Regarding the other controlled
substances listed, DEA has not received
quota applications from DEA-registered
manufacturers to support the requested
changes in the APQ for these controlled
substances. Mitragynine is not a
controlled substance and therefore is
outside the scope of this final order.
Issue: DEA-registered entities
requested that the APQ for Methadone,
Methadone Intermediate,
Methylphenidate Oxycodone (for sale),
Phenylacetone, and Thebaine be
sufficient to provide for the estimated
medical, scientific, research, and
industrial needs of the United States, for
export requirements, and for the
establishment and maintenance of
reserve stocks.
DEA Response: DEA sets APQ in a
manner to ensure that the estimated
medical, scientific, research, industrial
needs of the United States, lawful
export requirements, and for the
establishment and maintenance of
reserve stocks. As discussed in the
notice for adjustment, any adjustments
to the APQ for a controlled substance
are based on factors set forth in 21 CFR
1303.13. In the event of a shortage, the
CSA provides a mechanism under
which DEA will, in appropriate
circumstances, increase quotas to
address shortages. 21 U.S.C. 826(h).
Under 21 U.S.C. 826(h)(1), after
receiving a request to address a
shortage, DEA has 30 days to complete
review of the request and determine
whether adjustments are necessary to
address the shortage. If adjustments are
necessary, DEA is required to increase
the APQ and individual production
quotas to alleviate the shortage. Id. If
DEA determines adjustments are not
necessary, DEA is required to ‘‘provide
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
a written response detailing the basis for
the . . . determination.’’ Id. In addition
to what Section 826(h)(1) requires,
when DEA is notified of an alleged
shortage, DEA will confer with the Food
and Drug Administration and relevant
manufacturers regarding the amount of
material in physical inventory, current
quota granted, and the estimated
legitimate medical need, to determine
whether a quota adjustment is necessary
to alleviate any quota-related drug
shortage.
In accordance with 21 CFR 1303.13,
DEA considered the comments for
Bufotenine, 5-Methoxy-N,Ndimethyltryptamine (5MEODMT),
Ibogaine, Lysergic Acid Diethylamide
(LSD), Mescaline, Methadone,
Methadone Intermediate, Oxycodone
(for sale), and Thebaine and the
Administrator determined the proposed
adjusted 2021 APQs for these
substances as published in the Federal
Register on September 2, 2021, (86 FR
49346), are sufficient to meet the current
2021 estimated medical, scientific,
research, and industrial needs of the
United States, lawful export
requirements, and to provide for
adequate reserve stock.
Issue: Commenters expressed general
concerns regarding the inability to
submit electronic comments to the
notice published on September 2, 2021,
for two weeks. Commenters requested
an extension of the comment period to
allow for additional comments.
DEA Response: DEA acknowledges
that commenters could not submit
electronic comments to the notice for
two weeks. However, written comments
could be submitted via mail to the
address provided in the notice. Written
comments that were postmarked on or
before October 4, 2021, were considered
in this final order. DEA notes that one
commenter submitted identical
electronic and written comments both of
which were timely postmarked,
received, and considered for this final
order.
Out of Scope Comments: DEA
received comments on issues outside
the scope of this final order.
Commenters made several suggestions
to the DEA, including: (1) Seeking
assistance from indigenous
communities to determine the amount
of psychedelic substances that would be
needed to conduct research; (2) making
the United States a signatory to the
Nagoya Protocol and the Convention on
Biological Diversity; and (3) creating
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
diversified categories for production
and research on psilocybin-containing
fungi fruiting bodies/sclerotia/liquid
culture similar to cannabis (flower),
fruiting body extract (akin to cannabis
extract), and psilocybin and psilocin
separately as purified compounds (akin
to delta-9-thc). Regarding this last
suggestion, the commenter further
suggested that the ‘‘same system should
then be replicated in regards to
lophophora/mescaline, as well as other
plants, fungi and lifeforms, which
produce these compounds being used in
whole or closer to whole ways.’’
DEA received other comments that
were general in nature and raised issues
of specific medical illnesses and
medical treatments. All of the issues
raised are outside of the scope of this
final order for 2021 and do not impact
the original analysis involved in
finalizing the 2021 APQ.
Analysis for Final Adjusted 2021
Aggregate Production Quotas and
Assessment of Annual Needs
In determining the final adjusted 2021
APQ and AAN, DEA considered the
above comments relevant to this final
order for calendar year 2021, along with
the factors set forth in 21 CFR 1303.13
and 21 CFR 1315.13, in accordance with
21 U.S.C. 826(a). DEA has also
considered other relevant factors,
including the 2020 year-end inventories,
initial 2021 manufacturing and import
quotas, 2021 export requirements, actual
and projected 2021 sales, research and
product development requirements,
additional applications received, and
the extent of any diversion of the
controlled substance in the class. Based
on all of the above, the Administrator is
adjusting the 2021 APQ for the
following: 3,4Methylenedioxymethamphetamine
(MDMA), 4,4′-Dimethylaminorex,
Dimethyltryptamine (DMT),
Lisdexamfetamine, Methiopropamine,
Psilocybin, Psilocyn, and
Phenylacetone. This final order reflects
those adjustments.
Pursuant to the above, the
Administrator hereby finalizes the 2021
APQ for the following schedule I and II
controlled substances and the 2021
AAN for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
E:\FR\FM\15NON1.SGM
15NON1
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
63063
Final adjusted
2021
quotas
Basic class
(g)
khammond on DSKJM1Z7X2PROD with NOTICES
Schedule I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine ..................................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine ..................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ...........................................................................................................................
1-Benzylpiperazine ..............................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ...........................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...................................................................................................................................................
2’-fluoro 2-fluorofentanyl ......................................................................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ..........................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) .......................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) .........................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) .....................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ......................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36) ......................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ........................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82) .....................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) .............................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5) ................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ......................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine .....................................................................................................................................
2,5-Dimethoxyamphetamine (DMA) ....................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ...............................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ........................................................................................................
3,4,5-Trimethoxyamphetamine ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ..........................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) ...........................................................................................................................................
3–FMC; 3-Fluoro-N-methylcathinone ..................................................................................................................................................
3-Methylfentanyl ...................................................................................................................................................................................
3-Methylthiofentanyl .............................................................................................................................................................................
4′-Methyl acetyl fentanyl ......................................................................................................................................................................
4,4’-Dimethylaminorex .........................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ......................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) .................................................................................................................................
4-Chloro-a-pyrrolidinovalerophenone (4-chloro-alpha-PVP) ...............................................................................................................
4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide ...........................................................
4F–MDMB–BINACA ............................................................................................................................................................................
4-Fluoroisobutyryl fentanyl ...................................................................................................................................................................
4–FMC; Flephedrone ...........................................................................................................................................................................
4–MEC; 4-Methyl-N-ethylcathinone .....................................................................................................................................................
4-Methoxyamphetamine ......................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ......................................................................................................................................
4-Methylaminorex ................................................................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................
4-Methyl-a-ethylaminopentiophenone (4–MEAP) ...............................................................................................................................
4-Methyl-a-pyrrolidinohexiophenone (MPHP) .....................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ...............................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .........................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog) ..........................
5F–CUMYL–PINACA ...........................................................................................................................................................................
5F–EDMB–PINACA .............................................................................................................................................................................
5F–MDMB–PICA .................................................................................................................................................................................
5F–AB–PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ..........................................
5F–CUMYL–P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide) ...................................
5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ..........................
5F–AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ..................................................................
5F–APINACA; 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) .......................................................
5-Fluoro-PB–22; 5F–PB–22 ................................................................................................................................................................
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1H-indol- ......................................................................................................................
3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..................................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine .....................................................................................................................................................
AB–CHMINACA ...................................................................................................................................................................................
AB–FUBINACA ....................................................................................................................................................................................
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
E:\FR\FM\15NON1.SGM
15NON1
20
30
10
30
30
25
10
15
30
30
30
30
30
100
30
30
25
30
30
25
25
25
30
30
30
55
3,200
40
40
35
25
30
30
30
30
30
25
25
25
30
30
25
25
150
25
25
45
25
25
25
50
40
25
25
25
25
25
30
30
30
20
25
25
25
35
30
50
63064
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
Final adjusted
2021
quotas
Basic class
khammond on DSKJM1Z7X2PROD with NOTICES
(g)
AB–PINACA .........................................................................................................................................................................................
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .................................
Acetorphine ..........................................................................................................................................................................................
Acetyl Fentanyl ....................................................................................................................................................................................
Acetyl-alpha-methylfentanyl .................................................................................................................................................................
Acetyldihydrocodeine ...........................................................................................................................................................................
Acetylmethadol ....................................................................................................................................................................................
Acryl Fentanyl ......................................................................................................................................................................................
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....................................................
AH–7921 ..............................................................................................................................................................................................
All other tetrahydrocannabinol .............................................................................................................................................................
Allylprodine ..........................................................................................................................................................................................
Alphacetylmethadol ..............................................................................................................................................................................
alpha-Ethyltryptamine ..........................................................................................................................................................................
Alphameprodine ...................................................................................................................................................................................
Alphamethadol .....................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
alpha-Methylfentanyl ............................................................................................................................................................................
alpha-Methylthiofentanyl ......................................................................................................................................................................
alpha-Methyltryptamine (AMT) ............................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ..............................................................................................................................................
alpha-Pyrrolidinoheptaphenone (PV8) .................................................................................................................................................
alpha-Pyrrolidinohexanophenone (a-PHP) ..........................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................
Aminorex ..............................................................................................................................................................................................
Anileridine ............................................................................................................................................................................................
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) .........................................................................................
Benzethidine ........................................................................................................................................................................................
Benzylmorphine ...................................................................................................................................................................................
Betacetylmethadol ...............................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................
beta-Hydroxyfentanyl ...........................................................................................................................................................................
beta-Hydroxythiofentanyl .....................................................................................................................................................................
beta-Methyl fentanyl ............................................................................................................................................................................
beta-Phenyl fentanyl ............................................................................................................................................................................
Betameprodine .....................................................................................................................................................................................
Betamethadol .......................................................................................................................................................................................
Betaprodine ..........................................................................................................................................................................................
Brorphine .............................................................................................................................................................................................
Bufotenine ............................................................................................................................................................................................
Butylone ...............................................................................................................................................................................................
Butyryl fentanyl ....................................................................................................................................................................................
Cathinone .............................................................................................................................................................................................
Clonitazene ..........................................................................................................................................................................................
Codeine methylbromide .......................................................................................................................................................................
Codeine-N-oxide ..................................................................................................................................................................................
Cyclopentyl Fentanyl ...........................................................................................................................................................................
Cyclopropyl Fentanyl ...........................................................................................................................................................................
Cyprenorphine .....................................................................................................................................................................................
d-9–THC ..............................................................................................................................................................................................
Desomorphine ......................................................................................................................................................................................
Dextromoramide ..................................................................................................................................................................................
Diapromide ...........................................................................................................................................................................................
Diethylthiambutene ..............................................................................................................................................................................
Diethyltryptamine .................................................................................................................................................................................
Difenoxin ..............................................................................................................................................................................................
Dihydromorphine ..................................................................................................................................................................................
Dimenoxadol ........................................................................................................................................................................................
Dimepheptanol .....................................................................................................................................................................................
Dimethylthiambutene ...........................................................................................................................................................................
Dimethyltryptamine ..............................................................................................................................................................................
Dioxyaphetyl butyrate ..........................................................................................................................................................................
Dipipanone ...........................................................................................................................................................................................
Drotebanol ...........................................................................................................................................................................................
Ethylmethylthiambutene .......................................................................................................................................................................
Etorphine ..............................................................................................................................................................................................
Etoxeridine ...........................................................................................................................................................................................
Fenethylline ..........................................................................................................................................................................................
Fentanyl carbamate .............................................................................................................................................................................
Fentanyl related substances ................................................................................................................................................................
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
E:\FR\FM\15NON1.SGM
15NON1
30
30
25
100
30
30
25
25
50
30
1,000
25
25
25
25
25
25
30
30
25
25
25
25
25
25
20
25
25
30
25
30
30
30
30
30
25
4
25
30
15
25
30
40
25
30
192
30
20
25
384,460
25
25
20
20
25
9,200
753,500
25
25
20
3,200
25
25
25
25
30
25
30
30
600
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
63065
Final adjusted
2021
quotas
Basic class
khammond on DSKJM1Z7X2PROD with NOTICES
(g)
FUB–144 ..............................................................................................................................................................................................
FUB–AKB48 .........................................................................................................................................................................................
FUB–AMB, MMB-Fubinaca, AMB-Fubinaca .......................................................................................................................................
Furanyl fentanyl ...................................................................................................................................................................................
Furethidine ...........................................................................................................................................................................................
gamma-Hydroxybutyric acid ................................................................................................................................................................
Heroin ..................................................................................................................................................................................................
Hydromorphinol ....................................................................................................................................................................................
Hydroxypethidine .................................................................................................................................................................................
Ibogaine ...............................................................................................................................................................................................
Isobutyryl Fentanyl ...............................................................................................................................................................................
JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) .....................................................................................................................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ..........................................................................................................................................
JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ...........................................................................................................................................
JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) ......................................................................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ..........................................................................................................................
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ..............................................................................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ...........................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .......................................................................................................................
JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ...........................................................................................................................
Ketobemidone ......................................................................................................................................................................................
Levomoramide .....................................................................................................................................................................................
Levophenacylmorphan .........................................................................................................................................................................
Lysergic acid diethylamide (LSD) ........................................................................................................................................................
MAB–CHMINACA;
ADB–CHMINACA
(N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3carboxamide) ....................................................................................................................................................................................
MDMB–CHMICA; MMB–CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ...............
MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ..........................................
MMB–CHMICA-(AMB–CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate ............................
Marihuana ............................................................................................................................................................................................
Marihuana extract ................................................................................................................................................................................
Mecloqualone .......................................................................................................................................................................................
Mescaline .............................................................................................................................................................................................
Methaqualone ......................................................................................................................................................................................
Methcathinone .....................................................................................................................................................................................
Methiopropamine .................................................................................................................................................................................
Methyoxyacetyl fentanyl ......................................................................................................................................................................
Methyldesorphine .................................................................................................................................................................................
Methyldihydromorphine ........................................................................................................................................................................
Morpheridine ........................................................................................................................................................................................
Morphine methylbromide .....................................................................................................................................................................
Morphine methylsulfonate ....................................................................................................................................................................
Morphine-N-oxide ................................................................................................................................................................................
MT–45 ..................................................................................................................................................................................................
Myrophine ............................................................................................................................................................................................
NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate ................................................................................................
N,N-Dimethylamphetamine ..................................................................................................................................................................
Naphyrone ...........................................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................
N-Ethyl-3-piperidyl benzilate ................................................................................................................................................................
N-Ethylamphetamine ...........................................................................................................................................................................
N-Ethylhexedrone ................................................................................................................................................................................
N-Ethylpentylone, ephylone .................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
N-Methyl-3-Piperidyl Benzilate ............................................................................................................................................................
Nicocodeine .........................................................................................................................................................................................
Nicomorphine .......................................................................................................................................................................................
Noracymethadol ...................................................................................................................................................................................
Norlevorphanol .....................................................................................................................................................................................
Normethadone .....................................................................................................................................................................................
Normorphine ........................................................................................................................................................................................
Norpipanone ........................................................................................................................................................................................
Ocfentanil .............................................................................................................................................................................................
Ortho-fluorofentanyl, 2-fluorofentanyl ..................................................................................................................................................
ortho-Fluoroacryl fentanyl ....................................................................................................................................................................
ortho-Fluorobutyryl fentanyl .................................................................................................................................................................
ortho-Fluoroisobutyryl fentanyl ............................................................................................................................................................
ortho-Methyl acetylfentanyl ..................................................................................................................................................................
ortho-Methyl methoxyacetyl fentanyl ...................................................................................................................................................
Para-chloroisobutyryl fentanyl .............................................................................................................................................................
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
E:\FR\FM\15NON1.SGM
15NON1
25
25
25
30
25
29,417,000
45
40
25
30
25
35
45
45
30
30
35
30
30
30
30
25
25
40
30
30
30
25
2,000,000
500,000
30
25
60
25
30
30
5
25
25
5
5
150
30
25
25
25
25
25
10
24
25
30
24
30
25
25
25
2,550
25
40
25
25
30
30
30
30
30
30
30
63066
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
Final adjusted
2021
quotas
Basic class
(g)
Para-fluorofentanyl ...............................................................................................................................................................................
Para-fluorobutyryl fentanyl ...................................................................................................................................................................
para-Fluoro furanyl fentanyl .................................................................................................................................................................
para-Methylfentanyl .............................................................................................................................................................................
Para-methoxybutyryl fentanyl ..............................................................................................................................................................
Parahexyl .............................................................................................................................................................................................
PB–22; QUPIC .....................................................................................................................................................................................
Pentedrone ..........................................................................................................................................................................................
Pentylone .............................................................................................................................................................................................
Phenadoxone .......................................................................................................................................................................................
Phenampromide ...................................................................................................................................................................................
Phenomorphan ....................................................................................................................................................................................
Phenoperidine ......................................................................................................................................................................................
Phenyl fentanyl ....................................................................................................................................................................................
Pholcodine ...........................................................................................................................................................................................
Piritramide ............................................................................................................................................................................................
Proheptazine ........................................................................................................................................................................................
Properidine ...........................................................................................................................................................................................
Propiram ..............................................................................................................................................................................................
Psilocybin .............................................................................................................................................................................................
Psilocyn ................................................................................................................................................................................................
Racemoramide .....................................................................................................................................................................................
SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) .........................................................................................
SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ............................................................................................................
Tetrahydrofuranyl fentanyl ...................................................................................................................................................................
Thebacon .............................................................................................................................................................................................
Thiafentanil ..........................................................................................................................................................................................
Thiofentanyl .........................................................................................................................................................................................
Thiofuranyl fentanyl .............................................................................................................................................................................
THJ–2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ....................................................................................
Tilidine ..................................................................................................................................................................................................
Trimeperidine .......................................................................................................................................................................................
UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .....................................................................................
U–47700 ..............................................................................................................................................................................................
Valeryl fentanyl ....................................................................................................................................................................................
25
25
30
30
30
5
20
25
25
25
25
25
25
30
5
25
25
25
25
6,000
3,500
25
45
30
15
25
25
25
30
30
25
25
25
30
25
khammond on DSKJM1Z7X2PROD with NOTICES
Schedule II
1-Phenylcyclohexylamine ....................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ....................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .........................................................................................................................................
Alfentanil ..............................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
Amobarbital ..........................................................................................................................................................................................
Bezitramide ..........................................................................................................................................................................................
Carfentanil ............................................................................................................................................................................................
Cocaine ................................................................................................................................................................................................
Codeine (for conversion) .....................................................................................................................................................................
Codeine (for sale) ................................................................................................................................................................................
D-amphetamine (for sale) ....................................................................................................................................................................
D,l-amphetamine ..................................................................................................................................................................................
D-amphetamine (for conversion) .........................................................................................................................................................
Dextropropoxyphene ............................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................................
Dihydroetorphine ..................................................................................................................................................................................
Diphenoxylate (for conversion) ............................................................................................................................................................
Diphenoxylate (for sale) .......................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................................
Etorphine hydrochloride .......................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................................
Glutethimide .........................................................................................................................................................................................
Hydrocodone (for conversion) .............................................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................................................................
Hydromorphone ...................................................................................................................................................................................
Isomethadone ......................................................................................................................................................................................
L-amphetamine ....................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................
Levomethorphan ..................................................................................................................................................................................
Levorphanol .........................................................................................................................................................................................
Lisdexamfetamine ................................................................................................................................................................................
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
E:\FR\FM\15NON1.SGM
15NON1
15
25
937,758
3,260
25
20,100
25
20
68,576
1,612,500
27,616,684
21,200,000
21,200,000
16,068,789
35
156,713
25
14,100
770,800
68,576
30
32
731,452
25
1,250
30,821,224
2,743,101
30
30
25
30
26,495
22,500,000
Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices
63067
Final adjusted
2021
quotas
Basic class
(g)
L-methamphetamine ............................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Meperidine Intermediate-A ..................................................................................................................................................................
Meperidine Intermediate-B ..................................................................................................................................................................
Meperidine Intermediate-C ..................................................................................................................................................................
Metazocine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
D-methamphetamine (for conversion) .................................................................................................................................................
D-methamphetamine (for sale) ............................................................................................................................................................
Methylphenidate (for conversion) ........................................................................................................................................................
Methylphenidate (for sale) ...................................................................................................................................................................
Metopon ...............................................................................................................................................................................................
Moramide-intermediate ........................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Nabilone ...............................................................................................................................................................................................
Norfentanyl ...........................................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................................................................
Oliceridine ............................................................................................................................................................................................
Opium (powder) ...................................................................................................................................................................................
Opium (tincture) ...................................................................................................................................................................................
Oripavine ..............................................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxymorphone (for conversion) ............................................................................................................................................................
Oxymorphone (for sale) .......................................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phenazocine ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Phenylacetone .....................................................................................................................................................................................
Piminodine ...........................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Racemorphan ......................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Tapentadol ...........................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
587,229
856,695
30
30
30
15
25,619,700
27,673,600
50
485,020
40,000
15,300,000
57,438,334
25
25
3,376,696
26,505,995
62,000
25
22,044,741
376,000
22,500
250,000
530,837
33,010,750
620,887
57,110,032
28,204,371
563,174
30,766,670
25
35
25
6,100,000
25
5
5
3,000
172,100
4,000
13,447,541
57,137,944
List I Chemicals
Ephedrine (for conversion) ..................................................................................................................................................................
Ephedrine (for sale) .............................................................................................................................................................................
Phenylpropanolamine (for conversion) ................................................................................................................................................
Phenylpropanolamine (for sale) ...........................................................................................................................................................
Pseudoephedrine (for conversion) ......................................................................................................................................................
Pseudoephedrine (for sale) .................................................................................................................................................................
khammond on DSKJM1Z7X2PROD with NOTICES
The Administrator further proposes
that APQ for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero.
Anne Milgram,
Administrator.
[FR Doc. 2021–24921 Filed 11–10–21; 4:15 pm]
BILLING CODE 4410–09–P
[OMB Number 1117–0034]
Agency Information Collection
Activities; Proposed eCollection,
eComments Requested; Revision of a
Currently Approved Collection; The
National Forensic Laboratory
Information System Collection of
Analysis Data
Drug Enforcement
Administration, Department of Justice.
ACTION: 30-Day Notice.
AGENCY:
VerDate Sep<11>2014
16:42 Nov 12, 2021
Jkt 256001
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
The Department of Justice
(DOJ), Drug Enforcement
Administration (DEA), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
This proposed information collection
was previously published in the Federal
Register at 86 FR 47523 on August 25,
2021, allowing for a 60 day comment
period. No comments were received.
SUMMARY:
DEPARTMENT OF JUSTICE
100
4,136,000
14,878,320
16,690,000
1,000
174,246,000
E:\FR\FM\15NON1.SGM
15NON1
]]>Agencies
[Federal Register Volume 86, Number 217 (Monday, November 15, 2021)]
[Notices]
[Pages 63061-63067]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24921]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-688F]
Final Adjusted Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: This final order establishes the final adjusted 2021 aggregate
production quotas for controlled substances in schedules I and II of
the Controlled Substances Act and the assessment of annual needs for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: This order is effective November 15, 2021.
FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting
and Policy Support Section, Diversion Control Division, Drug
Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (571) 362-3261.
SUPPLEMENTARY INFORMATION:
Legal Authority
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
(APQ) for each basic class of controlled substances listed in schedules
I and II and for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney General has delegated this function
to the Administrator of the Drug Enforcement Administration (DEA)
pursuant to 28 CFR 0.100.
Background
DEA published the 2021 established APQ for controlled substances in
schedules I and II and for the assessment of annual needs (AAN) for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in
the Federal Register on November 30, 2020. 85 FR 76604. DEA is
committed to preventing and limiting diversion by enforcing laws and
regulations regarding controlled substances and the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the
legitimate medical, scientific, and export needs of the United States.
This notice stated that the Administrator would adjust, as needed, the
established APQ in 2021 in accordance with 21 CFR 1303.13 and 21 CFR
1315.13.
The 2021 proposed adjusted APQ for controlled substances in
schedules I and II and AAN for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine were subsequently published in
the Federal Register on September 2, 2021, (86 FR 49346), after
consideration of the criteria outlined in that notice. All interested
persons were invited to comment on or object to the proposed APQs and
AANs on or before October 4, 2021.
Comments Received
DEA received 27 timely comments in response to the September
Federal Register notice from patients, DEA-registered entities, and
non-DEA entities. The comments included appreciation of DEA's response
to the increased interest in research using hallucinogenic controlled
substances, requests to increase the APQ for additional hallucinogenic
controlled substances, requests to increase the APQ for select schedule
II controlled substances, concerns regarding the inability to comment
to the notice electronically for two weeks, and comments outside the
scope of this final order.
Issue: Commenters expressed appreciation of DEA's flexibility in
responding to the nationwide public interest in hallucinogenic
controlled substances research.
DEA Response: DEA acknowledges the expressions of appreciation to
changes in the APQ for these controlled substances. The adjustments to
select hallucinogenic schedule I controlled substances occurred after
DEA received additional schedule I researcher protocols from DEA
registered researchers and quota applications from DEA registered
manufacturers.
Issue: Commenters requested DEA to increase the APQ for Bufotenine,
Dimethyltryptamine (DMT), N,N-Dimethyltryptamine, 5-Methoxy-N,N-
[[Page 63062]]
dimethyltryptamine (5MEODMT), Ibogaine, Ketamine, Lysergic Acid
Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA),
Mescaline, Mitragynine, and Psilocybin in response to the nationwide
public interest in hallucinogenic controlled substances research.
DEA Response: Ketamine is a schedule III controlled substance and
therefore is outside of the scope of this final order as DEA only sets
APQs for substances controlled in schedules I and II. DEA received
additional quota applications for DMT, MDMA, and Psilocybin and
considered the timely provided information in those applications for
this final order. Regarding the other controlled substances listed, DEA
has not received quota applications from DEA-registered manufacturers
to support the requested changes in the APQ for these controlled
substances. Mitragynine is not a controlled substance and therefore is
outside the scope of this final order.
Issue: DEA-registered entities requested that the APQ for
Methadone, Methadone Intermediate, Methylphenidate Oxycodone (for
sale), Phenylacetone, and Thebaine be sufficient to provide for the
estimated medical, scientific, research, and industrial needs of the
United States, for export requirements, and for the establishment and
maintenance of reserve stocks.
DEA Response: DEA sets APQ in a manner to ensure that the estimated
medical, scientific, research, industrial needs of the United States,
lawful export requirements, and for the establishment and maintenance
of reserve stocks. As discussed in the notice for adjustment, any
adjustments to the APQ for a controlled substance are based on factors
set forth in 21 CFR 1303.13. In the event of a shortage, the CSA
provides a mechanism under which DEA will, in appropriate
circumstances, increase quotas to address shortages. 21 U.S.C. 826(h).
Under 21 U.S.C. 826(h)(1), after receiving a request to address a
shortage, DEA has 30 days to complete review of the request and
determine whether adjustments are necessary to address the shortage. If
adjustments are necessary, DEA is required to increase the APQ and
individual production quotas to alleviate the shortage. Id. If DEA
determines adjustments are not necessary, DEA is required to ``provide
a written response detailing the basis for the . . . determination.''
Id. In addition to what Section 826(h)(1) requires, when DEA is
notified of an alleged shortage, DEA will confer with the Food and Drug
Administration and relevant manufacturers regarding the amount of
material in physical inventory, current quota granted, and the
estimated legitimate medical need, to determine whether a quota
adjustment is necessary to alleviate any quota-related drug shortage.
In accordance with 21 CFR 1303.13, DEA considered the comments for
Bufotenine, 5-Methoxy-N,N-dimethyltryptamine (5MEODMT), Ibogaine,
Lysergic Acid Diethylamide (LSD), Mescaline, Methadone, Methadone
Intermediate, Oxycodone (for sale), and Thebaine and the Administrator
determined the proposed adjusted 2021 APQs for these substances as
published in the Federal Register on September 2, 2021, (86 FR 49346),
are sufficient to meet the current 2021 estimated medical, scientific,
research, and industrial needs of the United States, lawful export
requirements, and to provide for adequate reserve stock.
Issue: Commenters expressed general concerns regarding the
inability to submit electronic comments to the notice published on
September 2, 2021, for two weeks. Commenters requested an extension of
the comment period to allow for additional comments.
DEA Response: DEA acknowledges that commenters could not submit
electronic comments to the notice for two weeks. However, written
comments could be submitted via mail to the address provided in the
notice. Written comments that were postmarked on or before October 4,
2021, were considered in this final order. DEA notes that one commenter
submitted identical electronic and written comments both of which were
timely postmarked, received, and considered for this final order.
Out of Scope Comments: DEA received comments on issues outside the
scope of this final order. Commenters made several suggestions to the
DEA, including: (1) Seeking assistance from indigenous communities to
determine the amount of psychedelic substances that would be needed to
conduct research; (2) making the United States a signatory to the
Nagoya Protocol and the Convention on Biological Diversity; and (3)
creating diversified categories for production and research on
psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture
similar to cannabis (flower), fruiting body extract (akin to cannabis
extract), and psilocybin and psilocin separately as purified compounds
(akin to delta-9-thc). Regarding this last suggestion, the commenter
further suggested that the ``same system should then be replicated in
regards to lophophora/mescaline, as well as other plants, fungi and
lifeforms, which produce these compounds being used in whole or closer
to whole ways.''
DEA received other comments that were general in nature and raised
issues of specific medical illnesses and medical treatments. All of the
issues raised are outside of the scope of this final order for 2021 and
do not impact the original analysis involved in finalizing the 2021
APQ.
Analysis for Final Adjusted 2021 Aggregate Production Quotas and
Assessment of Annual Needs
In determining the final adjusted 2021 APQ and AAN, DEA considered
the above comments relevant to this final order for calendar year 2021,
along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13,
in accordance with 21 U.S.C. 826(a). DEA has also considered other
relevant factors, including the 2020 year-end inventories, initial 2021
manufacturing and import quotas, 2021 export requirements, actual and
projected 2021 sales, research and product development requirements,
additional applications received, and the extent of any diversion of
the controlled substance in the class. Based on all of the above, the
Administrator is adjusting the 2021 APQ for the following: 3,4-
Methylenedioxymethamphetamine (MDMA), 4,4'-Dimethylaminorex,
Dimethyltryptamine (DMT), Lisdexamfetamine, Methiopropamine,
Psilocybin, Psilocyn, and Phenylacetone. This final order reflects
those adjustments.
Pursuant to the above, the Administrator hereby finalizes the 2021
APQ for the following schedule I and II controlled substances and the
2021 AAN for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in grams of anhydrous acid or base, as
follows:
[[Page 63063]]
------------------------------------------------------------------------
Final adjusted
2021 quotas
Basic class ---------------
(g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine.................. 20
1-(1-Phenylcyclohexyl)pyrrolidine....................... 30
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.......... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)....... 30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)...... 30
1-Benzylpiperazine...................................... 25
1-Methyl-4-phenyl-4-propionoxypiperidine................ 10
1-[1-(2-Thienyl)cyclohexyl]piperidine................... 15
2'-fluoro 2-fluorofentanyl.............................. 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)........ 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)....... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)....... 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)..... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)................ 100
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
Cimbi-36)..............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)....... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
Cimbi-82)..............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)......... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
Cimbi-5)...............................................
2,5-Dimethoxy-4-ethylamphetamine (DOET)................. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine.............. 25
2,5-Dimethoxyamphetamine (DMA).......................... 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- 30
T-4)...................................................
3,4,5-Trimethoxyamphetamine............................. 30
3,4-Methylenedioxyamphetamine (MDA)..................... 55
3,4-Methylenedioxymethamphetamine (MDMA)................ 3,200
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............ 40
3,4-Methylenedioxy-N-methylcathinone (methylone)........ 40
3,4-Methylenedioxypyrovalerone (MDPV)................... 35
3-FMC; 3-Fluoro-N-methylcathinone....................... 25
3-Methylfentanyl........................................ 30
3-Methylthiofentanyl.................................... 30
4'-Methyl acetyl fentanyl............................... 30
4,4'-Dimethylaminorex................................... 30
4-Bromo-2,5-dimethoxyamphetamine (DOB).................. 30
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............. 25
4-Chloro-[alpha]-pyrrolidinovalerophenone (4-chloro- 25
alpha-PVP).............................................
4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2- 25
yl)-1H-indazole-3-carboximide..........................
4F-MDMB-BINACA.......................................... 30
4-Fluoroisobutyryl fentanyl............................. 30
4-FMC; Flephedrone...................................... 25
4-MEC; 4-Methyl-N-ethylcathinone........................ 25
4-Methoxyamphetamine.................................... 150
4-Methyl-2,5-dimethoxyamphetamine (DOM)................. 25
4-Methylaminorex........................................ 25
4-Methyl-N-methylcathinone (mephedrone)................. 45
4-Methyl-[alpha]-ethylaminopentiophenone (4-MEAP)....... 25
4-Methyl-[alpha]-pyrrolidinohexiophenone (MPHP)......... 25
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP)..... 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 50
phenol.................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 40
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)...
5F-CUMYL-PINACA......................................... 25
5F-EDMB-PINACA.......................................... 25
5F-MDMB-PICA............................................ 25
5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5- 25
fluoropentyl)-1H-indazole-3-carboxamide................
5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2- 25
yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide)...........
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H- 30
indazole-3-carboxamido)-3,3-dimethylbutanoate).........
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 30
carboxamido)-3-methylbutanoate)........................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5- 30
fluoropentyl)-1H-indazole-3-carboxamide)...............
5-Fluoro-PB-22; 5F-PB-22................................ 20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1H-indol-... 25
3-yl](2,2,3,3-tetramethylcyclopropyl)methanone..........
5-Methoxy-3,4-methylenedioxyamphetamine................. 25
5-Methoxy-N,N-diisopropyltryptamine..................... 25
5-Methoxy-N,N-dimethyltryptamine........................ 35
AB-CHMINACA............................................. 30
AB-FUBINACA............................................. 50
[[Page 63064]]
AB-PINACA............................................... 30
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 30
(4-fluorobenzyl)-1H-indazole-3-carboxamide)............
Acetorphine............................................. 25
Acetyl Fentanyl......................................... 100
Acetyl-alpha-methylfentanyl............................. 30
Acetyldihydrocodeine.................................... 30
Acetylmethadol.......................................... 25
Acryl Fentanyl.......................................... 25
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 50
pentyl-1H-indazole-3-carboxamide)......................
AH-7921................................................. 30
All other tetrahydrocannabinol.......................... 1,000
Allylprodine............................................ 25
Alphacetylmethadol...................................... 25
alpha-Ethyltryptamine................................... 25
Alphameprodine.......................................... 25
Alphamethadol........................................... 25
Alphaprodine............................................ 25
alpha-Methylfentanyl.................................... 30
alpha-Methylthiofentanyl................................ 30
alpha-Methyltryptamine (AMT)............................ 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)............. 25
alpha-Pyrrolidinoheptaphenone (PV8)..................... 25
alpha-Pyrrolidinohexanophenone ([alpha]-PHP)............ 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)............ 25
Aminorex................................................ 25
Anileridine............................................. 20
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3- 25
carboxamide)...........................................
Benzethidine............................................ 25
Benzylmorphine.......................................... 30
Betacetylmethadol....................................... 25
beta-Hydroxy-3-methylfentanyl........................... 30
beta-Hydroxyfentanyl.................................... 30
beta-Hydroxythiofentanyl................................ 30
beta-Methyl fentanyl.................................... 30
beta-Phenyl fentanyl.................................... 30
Betameprodine........................................... 25
Betamethadol............................................ 4
Betaprodine............................................. 25
Brorphine............................................... 30
Bufotenine.............................................. 15
Butylone................................................ 25
Butyryl fentanyl........................................ 30
Cathinone............................................... 40
Clonitazene............................................. 25
Codeine methylbromide................................... 30
Codeine-N-oxide......................................... 192
Cyclopentyl Fentanyl.................................... 30
Cyclopropyl Fentanyl.................................... 20
Cyprenorphine........................................... 25
d-9-THC................................................. 384,460
Desomorphine............................................ 25
Dextromoramide.......................................... 25
Diapromide.............................................. 20
Diethylthiambutene...................................... 20
Diethyltryptamine....................................... 25
Difenoxin............................................... 9,200
Dihydromorphine......................................... 753,500
Dimenoxadol............................................. 25
Dimepheptanol........................................... 25
Dimethylthiambutene..................................... 20
Dimethyltryptamine...................................... 3,200
Dioxyaphetyl butyrate................................... 25
Dipipanone.............................................. 25
Drotebanol.............................................. 25
Ethylmethylthiambutene.................................. 25
Etorphine............................................... 30
Etoxeridine............................................. 25
Fenethylline............................................ 30
Fentanyl carbamate...................................... 30
Fentanyl related substances............................. 600
[[Page 63065]]
FUB-144................................................. 25
FUB-AKB48............................................... 25
FUB-AMB, MMB-Fubinaca, AMB-Fubinaca..................... 25
Furanyl fentanyl........................................ 30
Furethidine............................................. 25
gamma-Hydroxybutyric acid............................... 29,417,000
Heroin.................................................. 45
Hydromorphinol.......................................... 40
Hydroxypethidine........................................ 25
Ibogaine................................................ 30
Isobutyryl Fentanyl..................................... 25
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)...... 35
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)................. 45
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)................. 45
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)..... 30
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)....... 30
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- 35
naphthoyl)indole)......................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)....... 30
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)...... 30
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)....... 30
Ketobemidone............................................ 30
Levomoramide............................................ 25
Levophenacylmorphan..................................... 25
Lysergic acid diethylamide (LSD)........................ 40
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1- 30
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide)...........................................
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)- 30
1H-indole-3-carboxamido)-3,3-dimethylbutanoate)........
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole- 30
3-carboxamido)-3,3-dimethylbutanoate)..................
MMB-CHMICA-(AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)- 25
1H-indole-3-carboxamido)-3-methylbutanoate.............
Marihuana............................................... 2,000,000
Marihuana extract....................................... 500,000
Mecloqualone............................................ 30
Mescaline............................................... 25
Methaqualone............................................ 60
Methcathinone........................................... 25
Methiopropamine......................................... 30
Methyoxyacetyl fentanyl................................. 30
Methyldesorphine........................................ 5
Methyldihydromorphine................................... 25
Morpheridine............................................ 25
Morphine methylbromide.................................. 5
Morphine methylsulfonate................................ 5
Morphine-N-oxide........................................ 150
MT-45................................................... 30
Myrophine............................................... 25
NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3- 25
carboxylate............................................
N,N-Dimethylamphetamine................................. 25
Naphyrone............................................... 25
N-Ethyl-1-phenylcyclohexylamine......................... 25
N-Ethyl-3-piperidyl benzilate........................... 10
N-Ethylamphetamine...................................... 24
N-Ethylhexedrone........................................ 25
N-Ethylpentylone, ephylone.............................. 30
N-Hydroxy-3,4-methylenedioxyamphetamine................. 24
N-Methyl-3-Piperidyl Benzilate.......................... 30
Nicocodeine............................................. 25
Nicomorphine............................................ 25
Noracymethadol.......................................... 25
Norlevorphanol.......................................... 2,550
Normethadone............................................ 25
Normorphine............................................. 40
Norpipanone............................................. 25
Ocfentanil.............................................. 25
Ortho-fluorofentanyl, 2-fluorofentanyl.................. 30
ortho-Fluoroacryl fentanyl.............................. 30
ortho-Fluorobutyryl fentanyl............................ 30
ortho-Fluoroisobutyryl fentanyl......................... 30
ortho-Methyl acetylfentanyl............................. 30
ortho-Methyl methoxyacetyl fentanyl..................... 30
Para-chloroisobutyryl fentanyl.......................... 30
[[Page 63066]]
Para-fluorofentanyl..................................... 25
Para-fluorobutyryl fentanyl............................. 25
para-Fluoro furanyl fentanyl............................ 30
para-Methylfentanyl..................................... 30
Para-methoxybutyryl fentanyl............................ 30
Parahexyl............................................... 5
PB-22; QUPIC............................................ 20
Pentedrone.............................................. 25
Pentylone............................................... 25
Phenadoxone............................................. 25
Phenampromide........................................... 25
Phenomorphan............................................ 25
Phenoperidine........................................... 25
Phenyl fentanyl......................................... 30
Pholcodine.............................................. 5
Piritramide............................................. 25
Proheptazine............................................ 25
Properidine............................................. 25
Propiram................................................ 25
Psilocybin.............................................. 6,000
Psilocyn................................................ 3,500
Racemoramide............................................ 25
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2- 45
methoxyphenylacetyl)indole)............................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30
Tetrahydrofuranyl fentanyl.............................. 15
Thebacon................................................ 25
Thiafentanil............................................ 25
Thiofentanyl............................................ 25
Thiofuranyl fentanyl.................................... 30
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3- 30
yl](naphthalen-1-yl)methanone).........................
Tilidine................................................ 25
Trimeperidine........................................... 25
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone.......................
U-47700................................................. 30
Valeryl fentanyl........................................ 25
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................. 15
1-Piperidinocyclohexanecarbonitrile..................... 25
4-Anilino-N-phenethyl-4-piperidine (ANPP)............... 937,758
Alfentanil.............................................. 3,260
Alphaprodine............................................ 25
Amobarbital............................................. 20,100
Bezitramide............................................. 25
Carfentanil............................................. 20
Cocaine................................................. 68,576
Codeine (for conversion)................................ 1,612,500
Codeine (for sale)...................................... 27,616,684
D-amphetamine (for sale)................................ 21,200,000
D,l-amphetamine......................................... 21,200,000
D-amphetamine (for conversion).......................... 16,068,789
Dextropropoxyphene...................................... 35
Dihydrocodeine.......................................... 156,713
Dihydroetorphine........................................ 25
Diphenoxylate (for conversion).......................... 14,100
Diphenoxylate (for sale)................................ 770,800
Ecgonine................................................ 68,576
Ethylmorphine........................................... 30
Etorphine hydrochloride................................. 32
Fentanyl................................................ 731,452
Glutethimide............................................ 25
Hydrocodone (for conversion)............................ 1,250
Hydrocodone (for sale).................................. 30,821,224
Hydromorphone........................................... 2,743,101
Isomethadone............................................ 30
L-amphetamine........................................... 30
Levo-alphacetylmethadol (LAAM).......................... 25
Levomethorphan.......................................... 30
Levorphanol............................................. 26,495
Lisdexamfetamine........................................ 22,500,000
[[Page 63067]]
L-methamphetamine....................................... 587,229
Meperidine.............................................. 856,695
Meperidine Intermediate-A............................... 30
Meperidine Intermediate-B............................... 30
Meperidine Intermediate-C............................... 30
Metazocine.............................................. 15
Methadone (for sale).................................... 25,619,700
Methadone Intermediate.................................. 27,673,600
Methamphetamine......................................... 50
D-methamphetamine (for conversion)...................... 485,020
D-methamphetamine (for sale)............................ 40,000
Methylphenidate (for conversion)........................ 15,300,000
Methylphenidate (for sale).............................. 57,438,334
Metopon................................................. 25
Moramide-intermediate................................... 25
Morphine (for conversion)............................... 3,376,696
Morphine (for sale)..................................... 26,505,995
Nabilone................................................ 62,000
Norfentanyl............................................. 25
Noroxymorphone (for conversion)......................... 22,044,741
Noroxymorphone (for sale)............................... 376,000
Oliceridine............................................. 22,500
Opium (powder).......................................... 250,000
Opium (tincture)........................................ 530,837
Oripavine............................................... 33,010,750
Oxycodone (for conversion).............................. 620,887
Oxycodone (for sale).................................... 57,110,032
Oxymorphone (for conversion)............................ 28,204,371
Oxymorphone (for sale).................................. 563,174
Pentobarbital........................................... 30,766,670
Phenazocine............................................. 25
Phencyclidine........................................... 35
Phenmetrazine........................................... 25
Phenylacetone........................................... 6,100,000
Piminodine.............................................. 25
Racemethorphan.......................................... 5
Racemorphan............................................. 5
Remifentanil............................................ 3,000
Secobarbital............................................ 172,100
Sufentanil.............................................. 4,000
Tapentadol.............................................. 13,447,541
Thebaine................................................ 57,137,944
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).............................. 100
Ephedrine (for sale).................................... 4,136,000
Phenylpropanolamine (for conversion).................... 14,878,320
Phenylpropanolamine (for sale).......................... 16,690,000
Pseudoephedrine (for conversion)........................ 1,000
Pseudoephedrine (for sale).............................. 174,246,000
------------------------------------------------------------------------
The Administrator further proposes that APQ for all other schedule
I and II controlled substances included in 21 CFR 1308.11 and 1308.12
remain at zero.
Anne Milgram,
Administrator.
[FR Doc. 2021-24921 Filed 11-10-21; 4:15 pm]
BILLING CODE 4410-09-P
